Computer Vision Systems (CVSL) Appoints Dr. David Fiorella to Its Scientific Advisory Board

BOCA RATON, Fla., April 9, 2012 (GLOBE NEWSWIRE) — Computer Vision Systems Laboratories Corp. (OTCBB:CVSL), announced today that it has appointed a new member to its Scientific Advisory Board.   Dr. David Fiorella has special interest in treatment of cerebrovascular disease and is not only an extremely experienced neurovascular doctor who uses guidewire technology, but also an inventor of state of the art medical devices for neurosurgery.

Dr. Fiorella is a Professor of Neurological Surgery and Radiology, having joined the Cerebrovascular Center at Stony Brook University Medical center in 2009 after faculty appointments at the Cleveland Clinic and the Barrow Neurological Institute. He is a Board-Certified Radiologist with CAQ in neuroradiology and fellowship training in Neuro-interventional Radiloogy/Endovascular Neurosurgery.   Dr. Fiorella has expertise in the diagnosis and treatment of stroke and cerebrovascular disease. He pioneered new technologies for treatment of complex cerebrovascular lesions.

In 2005 he performed the first three percutaneous angioplasty and stenting procedures for intracranial atherosclerosis with the Wingspan™ stent system in North America. Also he has nationally renowned expertise in the treatment of complex, giant aneurysms using novel technologies. Dr. Fiorella’s professional memberships include the Society of Neurointerventional Surgery and the American College of Radiology.

He is widely published in peer-reviewed journals such as Neurosurgery, Stroke, Journal of Neurosurgery and American Journal of Neuroradiology. He is National Co-Principal Investigator of the Stenting and Aggressive Medical Management for Preventing Recurrent stroke in Intracranial Stenosis trial (SAMMPRIS), funded by the National Institutes of Health. He is on the editorial board of the American Journal of Neurointerventional Radiology and is an associate Editor for the Journal of Neurointerventional Surgery.

Chief Executive Officer Thomas DiCicco, said, “We are very honored to add Dr. Fiorella to our Scientific Advisory Board. He has a proven track record pioneering new products for treatment of stroke, and had a keen interest in our maneuverable guidewire. Dr. Fiorella has met with the Company and identified areas in neuro surgery where our guidewire technology can be extremely useful,   We are in the process of evaluating the feasibility of some new features, that if successful, will be a very significant advancement in guidewire technology.”

About the Maneuverable Guidewire

This guidewire (US Patent 7,141,024 Nov 28, 2006) is unique, easy to use, and intended for use in all PTCA procedures. The maneuverable coiled guidewire is based on the “Buckling” theory in which the tip is bent according to the force applied to it. It is made of a high grade stainless steel PTFE (Teflon) coated coil and a thin wire disposed in it. The distal end of the coil is treated in such a way that when the inner wire is pulled the distal tip buckles and bends accordingly.  This feature is designed to allow the doctor to easily maneuver through the most tortuous vessels. CVSL plans to aggressively seek strategic partners through licensing agreements and joint ventures to manufacture and/or distribute the guidewire.

About the Sentinel BreastScan™

The Sentinel BreastScan is an advanced non-invasive infrared breast imaging system used as an adjunctive modality by doctors specializing in breast imaging and breast cancer treatment.   Utilizing infrared imaging and proprietary software employing artificial intelligence techniques, Sentinel BreastScan™ is designed to be used as an adjunctive test with mammography, ultrasound or clinical examination for the early detection of breast cancer. It is an FDA- 510k cleared, non-invasive touchless procedure offered to women of any age, to help determine current breast health. Test results are immediately available in the form of a fully-interpreted, objective report, to assist in the doctor’s determination of breast health.

We also plan to expand the role of our infrared imaging technology, in accordance with our FDA 510k, “indications for use” and devote R&D resources to the detection of skin cancer. Skin cancer has no approved imaging modalities and is detected by visual observation by a dermatologist followed by subsequent biopsy of suspicious lesions.   Our early research has shown the ability of our technology to detect certain invisible skin cancers.

About Computer Vision Systems Laboratories

Computer Vision System Laboratories Corp, is currently traded on the OTC BB and OTCQB under the symbol CVSL.   Computer Vision Systems Laboratories Corp, formerly Cardio Vascular Medical Device Corp. is a development-stage company. Computer Vision Systems Laboratories has obtained the worldwide exclusive license for the FDA cleared Sentinel BreastScan which focuses on early detection of breast cancer. Additionally, the company is focused on licensing, partnering, manufacturing and / or distributing our patented breakthrough maneuverable-coiled guidewire. CVSL will seek strategic partners in the industry with which it will promote its guidewire product. Parties interested in discussing the guidewire, Sentinel BreastScan, or investment opportunities may contact the CEO at thomasdicicco@CVSLAB.com.

CONTACT: thomasdicicco@CVSLAB.com
         Website: www.CVSLab.com
         Telephone: 1.888.406.5783